September 6, 2017 6:37pm

 

VSTM closed up +$1.08 or +28.13% with 20.7 M shares traded but was selling off from a day high of $5.55

As the sector slipped at the mid-day to the downside

 

Pre-open indications: 5 hits and 1 miss

Out and about: Verastem (VSTM) jumped on positive top-line results from its P3 study of duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and broadened its duvelisib development program to include targeting the treatment of patients with peripheral T-cell lymphoma.

 

It’s called premium content for a reason … I define insight  from a real-time perspective discussing equity share pricing, attractiveness and support levels as stock pricing changes by the hour … if not the minute!

A key question facing investors is this the … right time to invest in this corner of the market?

 

If you had been right as many times as I have been in these many months of 2017 as a SUBSCRIBER you would know … who and when to get in and out or get back in again!

 

I answer one question, in which company should investors commit and keep their money.

 

 

Wednesday’s results have implications to Thursday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!

 

 

Henry’omics:

From the pre-open’s investor’s newsletter “… looking down the barrel at a shot-up sector … should I be afraid; was but nope, been there, seen one and felt the dread. So watch, wait, listen and then execute your unit of measurement just like firing a weapon … depends on the distance, the wind speed and resistance as well as the elevation and devaluation. The cracking sound you hear is value, like any trajectory there is still “the feel” as Verastem (VSTM) could light up the sector.”

Cell and gene therapy companies were on the plus side at the open through the mid-day.

Feeling the gain was: BLUE< ONCE, VSTM, QURE and AGTC - the usual rotation after a severe drop. I believe AGTC has some … SERIOUS problems to deal with in relation to their trials that were supposed to have some data points in 2017.

Of the mid-tier stem cell companies; a number were up: ATHX, CLBS, MESO; ONVO and FATE (two of my favorites), ADVM and the consistent achiever and less than sometime loser AXGN.

Getting dumped in the relationship with sentiment was: JUNO, BLCM, CLLS, SGMO and BLFS (-$0.15) – another I told you so …!

And then there were the … tradeable: CYTX was down -$0.03 today after yesterdays – $0.01who announced a restructuring.

BSTG was down -$0.011 with 1.79 M sharers traded after yesterdays -$0.0223 to a wholesome $0.30 (sarcasm) with NO IND to be filed after spending $30 M, who can trust those in charge of a FAILED strategy.

Never forget CAPR (closing flat at $1.04) – another consistent loser with a failed development strategy – There are deeper issues there, so don’t define ANY FUTURE expectation with the current CEO.

IMUC was flat after being  down -$0.01, while ISCO was down -$0.04 after yesterday’s +$0.24 on 27.8 K shares traded <3 month average = 2.94 K shares> while PSTI was up +$0.04 after getting a grant of $8.7 M after yesterday’s drop of -$0.01 – says it all.

AST was down -$0.025 and BTX was up +$0.02 after riding to the rear of the sector as I had stated - both NEED to raise capital to keep the trials – on-going!

Under estimated companies: VCEL (closed flat at $4.30) with approved products and HSGX (-$0.05) with a P3 milestone.

I have been TELLING you for MONTHS …

 

Pre-open indications: 5 hits and 1 miss:

Applied Genetic Technologies (AGTC) closed up +$0.15 – miss;

 bluebird bio (BLUE) closed down -$1.05 – hit;

Cellectis SA (CLLS) closed down -$0.70 – hit;

 Juno Therapeutics (JUNO) closed down -$1.27 – hit;

 Sangamo Therapeutics (SGMO) closed down -$0.60 – hit;

Verastem (VSTM) closed up +$1.08 – hit;

 

The advance/decline line scenario of 43 SCGT & RT covered companies:   

·         The first hour was positive with an A/DL of 23/14 and 6 flats;

·         The mid-day was negative with an A/DL of 15/25 and 3 flat;

·         The close was negative with an A/DL of 18/22 and 3 flats ;

 

Out and about:

Verastem (VSTM) jumped on positive top-line results from its P3 study of duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).